menu
    • menu

    Company profile for Xbrane Biopharma

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Xbrane Biopharma AB is a biotechnology company which develops and manufactures biosimilars. Xbrane has a patented protein production platform and world-leading expertise within biosimilar development. Xbrane’s headquarter is located in Solna

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Xbrane BiopharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Banvaktsvägen 22 171 48 Solna Sweden
    Telephone
    Telephone
    +46 76-034 67 33
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://xbrane.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/1630164?trk=tyah&trkInfo=clickedVertical:company,clickedEntityId:1630164,idx:1-1-1,tarId:1477399504590,tas:xbrane
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/XbraneBiopharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alvotech Acquires Xbrane R&D Organization Cimzia Biosimilar
    Alvotech Acquires Xbrane R&D Organization Cimzia Biosimilar

    04 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/04/3093479/0/en/Alvotech-Completes-Acquisition-of-Xbrane-R-D-Organization-and-biosimilar-candidate-to-Cimzia.html

    GLOBENEWSWIRE
    04 Jun 2025
    Share Share
    Alvotech Acquires Xbrane’s R&D in Sweden, Strengthens Biosimilars
    Alvotech Acquires Xbrane’s R&D in Sweden, Strengthens Biosimilars

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045967/0/en/Alvotech-Acquires-Xbrane-s-R-D-Operations-in-Sweden-and-Further-Affirms-its-Global-Leadership-Position-in-Biosimilars-Development-and-Production.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo®
    Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo®

    22 May 2024

    // PRESS RELEASE

    https://xbrane.com/en/mfn_news/xbrane-successfully-scales-up-xdivane-biosimilar-candidate-to-opdivo-and-run-an-active-partnering-process/

    PRESS RELEASE
    22 May 2024
    Share Share
    iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
    iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar

    10 May 2024

    // ENDPTS

    https://endpts.com/iteos-to-raise-120m-xbrane-and-stada-to-out-license-lucentis-biosimilar/

    ENDPTS
    10 May 2024
    Share Share
    Xbrane provides reg update on FDA review of its ranibizumab biosimilar candidate
    Xbrane provides reg update on FDA review of its ranibizumab biosimilar candidate

    13 Apr 2024

    // PRESS RELEASE

    https://xbrane.com/en/mfn_news/xbrane-provides-regulatory-update-on-fda-review-of-its-ranibizumab-biosimilar-candidate/

    PRESS RELEASE
    13 Apr 2024
    Share Share
    Stada and Xbrane gain EU approval for biosimilar Ximluci
    Stada and Xbrane gain EU approval for biosimilar Ximluci

    11 Nov 2022

    // PHARMATIMES

    https://www.pharmatimes.com/news/stada_and_xbrane_gain_eu_approval_for_biosimilar_ximluci_1480676

    PHARMATIMES
    11 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search